KRAS and lung cancer: KRAS-mutant lung cancer bone metastasis tissue exhibited higher p-STAT3Tyr705 levels at day 28 after intracardiac injection than at day 7 (Fig. 6c), suggesting that activation of IL6/JAK/STAT3 pathway may be involved in the enhanced resistance to HOXC10 inhibition.